Replies to post #240079 on Avid Bioservices Inc (CDMO)

[sunstar]

Thanks, 42 clinical studies listed for Tremelimumab AstraZeneca/MedImmune.

Recruiting Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).

Condition: Non-Small-Cell Lung Carcinoma (NSCLC)

Interventions: Biological: MEDI4736; Biological: MEDI4736+Tremelimumab; Drug: Paclitaxel + Carboplatin; Drug: Gemcitabine + Cisplatin; Drug: Gemcitabine + Carboplatin; Drug: Pemetrexed + Cisplatin; Drug: Pemetrexed + Carboplatin; Biological: Tremelimumab

Estimated Enrollment: 675
Study Start Date: July 2015
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)

https://clinicaltrials.gov/ct2/show/NCT02453282?term=tremelimumab+phase+III&rank=1

IMO

sunstar